Effective Cannabis | Research & Blog
A potentially disabling disease of the brain and spinal cord (central nervous system). In MS, the immune system attacks the protective sheath (myelin) that covers nerve fibers and causes communication problems between your brain and the rest of your body.
In 2018, After a review of scientific studies, researchers say extracts from marijuana plants can help treat pain and spasticity symptoms in people with multiple sclerosis. Background: looked at the safety and effectiveness of cannabis as well as studying its impact on disability and disability progression, pain, spasticity, bladder function, tremor/ataxia, quality of life, and .. Read More
In 2009, Cannabinoids as pharmacotherapies for neuropathic pain: nerve injury, diabetes, chemotherapeutic treatment, human immunodeficiency virus, multiple sclerosis, and herpes zoster infection is considered. Background: review of clinical and preclinical literature evaluating CB1, CB2, THC You can read the full article here =>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2755639/
In 2018, Studied the safety and efficacy of medical cannabis in elderly treatments of 2736 patients. Background: A prospective study that included all patients above 65 years of age who received medical cannabis from January 2015 to October 2017. You can read the full article here => https://multiplesclerosisnewstoday.com/2018/02/20/medical-cannabis-treats-chronic-pain-older-multiple-sclerosis-other-patients-report/?utm_content=buffer09fa0&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer
In 2012, A 12 week study using Cannabis Extract for muscle stiffness associated with Multiple Sclerosis Patients aged 18-64 years Background: Double blind, placebo controlled, with a 2 week dose titration phase from 5 mg to a maximum of 25 mg of THC daily and a 10 week maintenance phase. You can read the full article here => https://www.researchgate.net/publication/229082908_MUltiple_Sclerosis_and_Extract_of_Cannabis_results_of_the_MUSEC_trial
In 2007, Uncontrolled patient trial of THC/cannabidiol for neuropathic pain associated with multiple sclerosis with a 2-year extension trial. Background: 64 males completed the randomized trial and 63 entered the open-label extension. age, range, 27–71 years. You can read the full article here => http://www.clinicaltherapeutics.com/article/S0149-2918(07)00294-9/
in 2014, A Review of (THC)/cannabidiol (CBD) [Sativex® Its Use in Patients with Moderate to Severe Spasticity Due to Multiple Sclerosis BACKGROUND: 12 weeks’ double-blind treatment with THC/CBD You can read the full article here => http://link.springer.com/article/10.1007%2Fs40265-014-0197-5
In 2012, MS has been considered mainly an inflammatory disorder, recent evidence, however, revealed the importance of neurodegenerative events, opening the possibility to cannabinoid treatment. Mice were used BACKGROUND: Treatment with WIN55,512-2, a potent CB1 and CB2agonist, was reported to be effective to ameliorate tremor and spasticity in mice with chronic relapsing experimental autoimmune encephalomyelitis, You .. Read More
